Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X. Zhu, Yvonne H. Sada, Sadahisa Ogasawara et al.|The Lancet Oncology|2018Cited by 2.5k
Association between neutrophil–lymphocyte ratio, socioeconomic status, and ethnic minority with treatment outcome in hepatocellular carcinomaYifei Zhang, Rafi Kabarriti, Nitin Ohri et al.|Hepatology International|2019Cited by 9